122 related articles for article (PubMed ID: 639435)
1. Allopurinol kinetics.
Hande K; Reed E; Chabner B
Clin Pharmacol Ther; 1978 May; 23(5):598-605. PubMed ID: 639435
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide.
Breithaupt B; Tittel M
Eur J Clin Pharmacol; 1982; 22(1):77-84. PubMed ID: 7094977
[TBL] [Abstract][Full Text] [Related]
3. Allopurinol kinetics and bioavailability. Intravenous, oral and rectal administration.
Appelbaum SJ; Mayersohn M; Dorr RT; Perrier D
Cancer Chemother Pharmacol; 1982; 8(1):93-8. PubMed ID: 7094203
[TBL] [Abstract][Full Text] [Related]
4. Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone.
Colin JN; Farinotti R; Fredj G; Tod M; Clavel JP; Vignon E; Dietlin F
Eur J Clin Pharmacol; 1986; 31(1):53-8. PubMed ID: 3780828
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a thiazide-allopurinol drug interaction.
Hande KR
Am J Med Sci; 1986 Oct; 292(4):213-6. PubMed ID: 3752167
[TBL] [Abstract][Full Text] [Related]
6. [Time course of oxipurinol levels in plasma following single dose and chronic administration of allopurinol in different pharmaceutical preparations (author's transl)].
Walter-Sack I; Gröbner W; Zöllner N
Arzneimittelforschung; 1979; 29(5):839-42. PubMed ID: 582985
[TBL] [Abstract][Full Text] [Related]
7. [A study of serum oxipurinol concentration and renal function in patients administered allopurinol].
Saji M
Nihon Jinzo Gakkai Shi; 1996 Dec; 38(12):640-50. PubMed ID: 9014485
[TBL] [Abstract][Full Text] [Related]
8. Sustained reductions in oxipurinol renal clearance during a restricted diet.
Park GD; Berlinger WG; Spector R; Kitt TM; Tsalikian E
Clin Pharmacol Ther; 1987 Jun; 41(6):616-21. PubMed ID: 3581647
[TBL] [Abstract][Full Text] [Related]
9. [Clinical pharmacokinetics of allopurinol. 3. Allopurinol/oxipurinol pharmacokinetics following administration of a controlled release allopurinol preparation].
Gikalov I; Radivojevich F; Schiemann O; Fenner H
Arzneimittelforschung; 1986 Jun; 36(6):988-93. PubMed ID: 3741536
[TBL] [Abstract][Full Text] [Related]
10. [The clinical pharmacokinetics of allopurinol. 1. Allopurinol absorption sites and dose proportionality of allopurinol/oxipurinol bioavailability].
Schuster O; Haertel M; Hugemann B; Gikalov I; Schiemann O; Fenner H
Arzneimittelforschung; 1985; 35(4):760-5. PubMed ID: 4015743
[TBL] [Abstract][Full Text] [Related]
11. Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects. II. Kinetics of allopurinol, oxipurinol, and hydrochlorothiazide.
de Vries JX; Voss A; Ittensohn A; Walter-Sack I; Löffler W; Landthaler R; Zöllner N
Clin Investig; 1994 Dec; 72(12):1076-81. PubMed ID: 7711419
[TBL] [Abstract][Full Text] [Related]
12. Dosage prescribing and plasma oxipurinol levels in patients receiving allopurinol therapy.
Peterson GM; Boyle RR; Francis HW; Oliver NW; Paterson J; von Witt RJ; Taylor GR
Eur J Clin Pharmacol; 1990; 39(4):419-21. PubMed ID: 2076730
[TBL] [Abstract][Full Text] [Related]
13. [Influence of benzbromarone on the pharmacokinetics and pharmacodynamics of oxipurinol].
Rüffer C; Zorn G; Henkel E; Mitzkat HJ
Arzneimittelforschung; 1982; 32(9):1149-52. PubMed ID: 6890841
[TBL] [Abstract][Full Text] [Related]
14. Oxipurinol: alloxanthine, Oxyprim, oxypurinol.
Drugs R D; 2004; 5(3):171-5. PubMed ID: 15139781
[TBL] [Abstract][Full Text] [Related]
15. Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol.
Day RO; Miners J; Birkett DJ; Graham GG; Whitehead A
Br J Clin Pharmacol; 1988 Oct; 26(4):429-34. PubMed ID: 3190993
[TBL] [Abstract][Full Text] [Related]
16. A simple method for quantification of allopurinol and oxipurinol in human serum by high-performance liquid chromatography with UV-detection.
Reinders MK; Nijdam LC; van Roon EN; Movig KL; Jansen TL; van de Laar MA; Brouwers JR
J Pharm Biomed Anal; 2007 Oct; 45(2):312-7. PubMed ID: 17890037
[TBL] [Abstract][Full Text] [Related]
17. Demonstration of a combined deficiency of xanthine oxidase and aldehyde oxidase in xanthinuric patients not forming oxipurinol.
Reiter S; Simmonds HA; Zöllner N; Braun SL; Knedel M
Clin Chim Acta; 1990 Mar; 187(3):221-34. PubMed ID: 2323062
[TBL] [Abstract][Full Text] [Related]
18. Allopurinol metabolism in a patient with xanthine oxidase deficiency.
Yamanaka H; Nishioka K; Suzuki T; Kohno K
Ann Rheum Dis; 1983 Dec; 42(6):684-6. PubMed ID: 6689118
[TBL] [Abstract][Full Text] [Related]
19. Bioavailability of allopurinol oral and rectal dosage forms.
Chang SL; Kramer WG; Feldman S; Ballentine R; Frankel LS
Am J Hosp Pharm; 1981 Mar; 38(3):365-8. PubMed ID: 7223751
[TBL] [Abstract][Full Text] [Related]
20. [Excretion and serum concentrations of allopurinol, oxipurinol and oxipurines in combined treatment with allopurinol and benzbromarone in increasing doses].
Mertz DP; Borner K
Med Welt; 1983 Sep; 34(36):974-9. PubMed ID: 6633222
[No Abstract] [Full Text] [Related]
[Next] [New Search]
